Smaart Medical Systems, Inc

Form 483 issued May 9, 2025 · Dallas, Texas

Inspection
May 5 – May 9, 2025
Observations
13
Pages
13
FEI number
3025620599

In short: On May 9, 2025, FDA issued a Form 483 with 13 observations to Smaart Medical Systems, Inc in Dallas, Texas (FEI 3025620599) after an inspection that ran May 5 – May 9, 2025. The investigators were Elizabeth A. Krolczyk and Jocelyn C. Turner. Most observations concern production & process controls and cAPA; the most-cited regulation is 21 CFR 820.30 (design controls).

At a glance

Observations span 4 systems, led by production & process controls.

Production & process controls3
CAPA3
Management controls3
Design controls2
Other2

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures for design control…

  2. 02

    Procedures for design validation…

  3. 03

    Software used as part of the quality system has not been validated for its intended use…

  4. 04

    Written MDR procedures have…

9 more observations

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Smaart Medical Systems, Inc?

FDA listed 13 observations on this Form 483, mostly about production & process controls, cAPA and management controls. The most-cited regulation is 21 CFR 820.30 (design controls). The opening words of each observation are shown on this page.

Who inspected Smaart Medical Systems, Inc?

Elizabeth A. Krolczyk and Jocelyn C. Turner are named on this Form 483, for the inspection of May 5 – May 9, 2025. Each investigator has a profile showing what they cite most.

When was Smaart Medical Systems, Inc inspected by FDA?

The inspection ran May 5 – May 9, 2025, and the Form 483 is dated May 9, 2025.

How do I get the full Form 483 for Smaart Medical Systems, Inc?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free